Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 2,377 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Visual Function Tests in Age-related Macular Degeneration

NCT03275753
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Visual Function Tests
Other
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

NCT00241319
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
Indianapolis, Indiana • Lewiston, Maine • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

NCT03691649
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Test the Safety and Feasibility of a Brillouin Ocular Analyzer

NCT01775007
View directory record Official record
Conditions
Measurement of the Elasticity of the Anterior Eye Segment
Interventions
Brillouin Ocular Analyser
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 24, 2026, 4:59 AM EDT
Completed No phase listed Observational

Screening for NEI Clinical Studies

NCT00001734
View directory record Official record
Conditions
Conjunctivitis, Iritis, Keratitis, Retinitis, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

NCT04405245
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
Latanoprost ophthalmic solution, AKB-9778 4%, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
21
States / cities
Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 4 Interventional Results available

24-hour IOP-lowering Effect of Brimonidine 0.1%

NCT00457795
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
brimonidine 0.1% (Alphagan® P)
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 24, 2026, 4:59 AM EDT
Terminated Not applicable Interventional

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

NCT02327312
View directory record Official record
Conditions
Primary Open-Angle Glaucoma
Interventions
Stents, Laser, Laser Trabeculoplasty
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
35 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Hemet, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

NCT01835145
View directory record Official record
Conditions
Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Cabozantinib S-malate, Dacarbazine, Laboratory Biomarker Analysis, Temozolomide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
224
States / cities
Birmingham, Alabama • Anchorage, Alaska • Burbank, California + 141 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Idiopathic Intracranial Hypertension Treatment Trial

NCT01003639
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Placebo, Formal weight loss counselling program
Drug · Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)

NCT02911116
View directory record Official record
Conditions
Uveitis
Interventions
Ustekinumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

NCT03858894
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
13
States / cities
Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 24, 2026, 4:59 AM EDT
Active, not recruiting No phase listed Observational

Anterior Segment Optical Coherence Tomography Microstent Positioning

NCT06666751
View directory record Official record
Conditions
Glaucoma, Stent Migration, Stent Dislodgement, Intraocular Pressure
Interventions
Cataract plus Microstent surgery
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 100 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 4:59 AM EDT
Recruiting Phase 3 Interventional

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141
View directory record Official record
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

NCT01977781
View directory record Official record
Conditions
Ocular GVHD
Interventions
Tacrolimus, Methylprednisolone Sodium Succinate
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 3 Interventional

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

NCT00800267
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
53
States / cities
Anaheim, California • Sacramento, California • San Francisco, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 24, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional Results available

Combined Patching-Atropine for Residual Amblyopia

NCT00506675
View directory record Official record
Conditions
Amblyopia
Interventions
Patching, Atropine
Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 9 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Glaucoma Evaluation With the P200TE

NCT06305481
View directory record Official record
Conditions
Glaucoma
Interventions
P200TE
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Cajon, California • Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 4:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Extension Study to Study PQ-110-001 (NCT03140969)

NCT03913130
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions
QR-110
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
6 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Iowa City, Iowa • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 24, 2026, 4:59 AM EDT
Completed No phase listed Observational

Flare Measurements in Human Radiation Therapy Patients

NCT01640236
View directory record Official record
Conditions
The Impact of Whole Body Irradiation on Ocular Flare
Interventions
Not listed
Lead sponsor
ChromoLogic, LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Not applicable Interventional

The Effect of Punctal Plugs on Ocular Surface After Povidone-Iodine Preparation of Intravitreal Injection

NCT03945071
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye, Ocular Surface Disease
Interventions
Punctal plug
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 24, 2026, 4:59 AM EDT
Not listed Early Phase 1 Interventional

Effectiveness of Virtual Reality Vision Therapy - VERVE

NCT04691427
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Virtual Eye Rotation Vision Exercises (VERVE)
Device
Lead sponsor
OculoMotor Technologies
Industry
Eligibility
9 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Newark, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

Predictors of Driving Performance and Successful Mobility - Rehabilitation in Patients With Medical Eye Condition

NCT00013377
View directory record Official record
Conditions
Low Vision
Interventions
Low vision
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 24, 2026, 4:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability

NCT01013077
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Optive, Soothe, New Emulsion, Soothe, New Emulsion, Optive, New Emulsion, Optive, Soothe
Other
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 24, 2026, 4:59 AM EDT